Eloxx Pharmaceuticals (ELOX) analyst forecast and price target
Analyst forecast
Consensus of 4 analyst ratings
Based on 4 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Cantor Fitzgerald | Initiated Coverage | Overweight | — | Oct 15, 2026 |
| Leerink Partners | Initiated Coverage | Outperform | $32.00 | Sep 18, 2026 |
| Guggenheim | Maintained | Buy | $43.00 | Aug 24, 2026 |
| LUCID CAPITAL MARKETS | Initiated Coverage | Buy | $38.00 | Aug 20, 2026 |
| LifeSci Capital | Initiated Coverage | Outperform | $40.00 | Jul 22, 2026 |
| Guggenheim | Initiated Coverage | Buy | $43.00 | Jul 20, 2026 |
Frequently asked questions
What is the price target for ELOX stock?
The average 12-month analyst price target for Eloxx Pharmaceuticals (ELOX) is $38.25, with a high estimate of $43.00 and a low of $32.00, across 4 analysts.
Is ELOX a buy, sell, or hold?
Analysts covering Eloxx Pharmaceuticals currently average a Buy rating: 4 buy, 0 hold and 0 sell, from 4 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for ELOX?
The average price target of $38.25 implies 213.27% upside from the last price of $12.21.
What is the latest analyst rating on ELOX?
On Oct 15, 2026, Cantor Fitzgerald initiated coverage of Eloxx Pharmaceuticals at Overweight.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.